PeptideNerds

Melanotan I Benefits

FDA ApprovedOther
PN

Reviewed by Peptide Nerds Editorial · Updated March 2026

Not medical advice. This content is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer.

How Melanotan I works

Selectively binds melanocortin-1 receptors (MC1R) on melanocytes, stimulating eumelanin production through a cAMP-dependent signaling cascade. Unlike Melanotan II, MT-I does not significantly activate MC3R, MC4R, or MC5R, resulting in pigmentation effects without the sexual function, appetite, or cardiovascular side effects associated with non-selective melanocortin agonism.

Reported benefits

Based on published clinical trials, Melanotan I has been associated with the following benefits:

  • FDA-approved for erythropoietic protoporphyria (EPP) as Scenesse
  • Selective MC1R activation produces pigmentation without sexual side effects
  • Increased pain-free sun exposure in EPP patients (median 10 min to 180 min)
  • Enhanced photoprotection through increased eumelanin in skin
  • Reduced phototoxic reactions by approximately 47% in clinical trials
  • Long-lasting pigmentation effect (weeks) due to melanin deposition in keratinocytes

Supporting research

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine, 2015 · PMID: 26132941

Pivotal trial demonstrated increased pain-free sun exposure and reduced phototoxic reactions in EPP patients. Led to FDA approval.

Three-year observational study of afamelanotide in erythropoietic protoporphyria

British Journal of Dermatology, 2020 · PMID: 32811524

Phototoxic burn tolerance increased from median 10 minutes to 180 minutes, with 97.4% treatment adherence over 3 years.

Tanning and cutaneous melanin synthesis with subcutaneous melanotan-I and UV exposure

Journal of Investigative Dermatology, 2004 · PMID: 15262693

MT-I combined with UV produced 47% fewer sunburn cells and prolonged tanning versus UV alone, with controls requiring 50% more sun exposure.

Important context

Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors.

OverviewDosageSide EffectsFAQ

Related peptides

Melanotan II — Skin pigmentation enhancement: Phase I trial demonstrated measurable increases in facial, upper body, and genital skin pigmentation in 2 of 3 healthy volunteers receiving subcutaneous MT-II at 0.01-0.03 mg/kg. Tanning occurred with significantly less UV exposure than required naturally (PMID: 8637402).PT-141 — FDA-approved for HSDD in women

Weekly peptide research updates

New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.